Cancer supportive care isassociated with care given to the patients suffering from various types ofcancer. Supportive care is intended for relieving suffering of the patients andimproving their quality of life.
Statistics:
The global CancerSupportive Care Products Market was estimated to account for US$ 27,244. Mnin terms of value by the end of 2019.
Global Cancer Supportive CareProducts Market: Drivers
Availability of effective cancersupportive care products is expected to propel growth of the global cancersupportive care products market over the forecast period. For instance,according to a study presented at the recent Digital International LiverCongress (ILC 2020), Stivarga (regorafenib) and Opdivo (nivolumab), whenadministered as second-line treatments, equally improve survival for peoplewith hepatocellular carcinoma (HCC), the most common type of liver cancer.
Global Cancer Supportive CareProducts Market: Opportunities
R&D in drug delivery incancer pain care is expected to offer lucrative growth opportunities forplayers in the global cancer supportive care products market. For instance, inAugust 2020, a study by Center for Pain and Supportive Care in Phoenix,Arizona, U.S., supported the use of intrathecal drug delivery in cancer paincare.
Global Cancer Supportive CareProducts Market: Restraints
Rising cost of R&D isexpected to hinder growth of the global cancer supportive care products market.A new study ‘Estimated Research and Development Investment Needed to Bring aNew Medicine to Market, 2009-2018’, published in March 2020 estimated that themedian cost of getting a new drug into the market was US$ 985 million.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2013
Key Takeaways:
The global cancer supportive careproducts market was valued at US$ 27,244.1 Mn in 2019 and is forecast to reacha value of US$ 40,884.0 Mn by 2027 at a CAGR of 4.6% between 2020 and2027.Increseing prevalence of cancer in developing and developed economies isexpected to drive the market growth during the forecast period.
Erythropoietin Stimulating Agentssegment held dominant position in the global cancer supportive care productsmarket in 2019, accounting for 24.7% share in terms of value, increasingresearch and development along with product approvals is expected to assist thesegment growth during the forecast period.
Market Trends
Emergence of COVID‐19 has impactedcancer supportive care. For instance, the French Society of Pediatric Oncology,in September 2020, reported that, in a survey, out of the 12 centers thatmanaged COVID‐19 patients, eight centers declared having postponed a specificoncologic treatment because of suspected or confirmed infection. Eight centers(28.6%) declared facing health care providers’ absenteeism because ofinfection.
Launch of cancer care qualityimprovement model is expected to propel growth of the global cancer supportivecare products market over the forecast period. For instance, in August 2020, aquality improvement tool called “Improving Care Coordination: A Model for LungCancer” was released by the Association of Community Cancer Centers (ACCC).Themodel framework can be used by cancer care providers to improve carecoordination for patients with lung cancer who are covered by Medicaid.
Regulations
Regulations (EU) - CancerSupportive Care
Approval Process
Cancer drugs are licensed in theEU by the EMA and their various regulatory aspects can be found underdirectives 2001/83/EC, CPMP/EWP/83561/2005, CPMP/EWP/2330/99 and others
EMA also recommends understandingthe drug-drug interactions assessment, mass-balance studies related topharmacokinetics of cancer-supportive drugs
Assessment of drug-druginteraction are also strongly recommended under directive CPMP/EWP/560/95/Rev.1
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/cancer-supportive-care-drugs-market-2013
Special instructions from EMA andEFPIA for development of products to be used for cancer supportive care
Clinical efficacy measurement ofthe drug should strongly be inclined towards adequacy of management of nauseaand vomiting – even if delayed
Acronyms and tables detailingnausea and vomiting symptoms, along with their pathophysiology should be welldocumented
There needs to be more emphasison understanding the carryover effect between controlling chemotherapy inducedemesis symptoms. As such, the EFPIA has recommended randomization of at leastone drug approval trial
Further, it is inappropriate tomention only one drug as a standard therapy e.g. NK1 receptor antagonist as astandard antiemetic therapy. It is better from the ethical standpoint tomention comparable drug data form the research perspective
Global Cancer Supportive CareProducts Market: Competitive Landscape
Major players operating in theglobal cancer supportive care products market include, Amgen Inc., Johnson& Johnson Private Ltd., Merck, Novartis AG, Baxter International,Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 TherapeuticsInc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono, and KyowaHakko Kirin Co., Ltd.
Global Cancer Supportive Care ProductsMarket: Key Developments
Major players in the market arefocused on approval and launch of new products to expand their productportfolio. For instance, For instance, in August 2020, G1 Therapeutics Inc.received the U.S. FDA’s priority review designation to a new drug application(NDA) for trilaciclib for the treatment of patients with small cell lung cancer(SCLC) who are being treated with chemotherapy.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2013
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
